Evidence map›Paper›PMID 30036382›Full record

SynthesisPLoS neglected tropical diseases2018

Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016.

Madeleine H A Clark, George M Warimwe, Antonello Di Nardo, Nicholas A Lyons, Simon Gubbins

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 7 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 7 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Altered histone modifications inbioRxiv : the preprint server for biology · 2025
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Madeleine H A ClarkTransmission Biology Group, The Pirbright Institute, Pirbright, Woking, United Kingdom.ORCID 0000-0001-9532-7927
George M WarimweBiosciences Department, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Antonello Di NardoVesicular Disease Reference Laboratories, The Pirbright Institute, Pirbright, Woking, United Kingdom.
Nicholas A LyonsVesicular Disease Reference Laboratories, The Pirbright Institute, Pirbright, Woking, United Kingdom.
Simon GubbinsTransmission Biology Group, The Pirbright Institute, Pirbright, Woking, United Kingdom.ORCID 0000-0003-0538-4173
The Pirbright Institute · GBKenya Medical Research Institute · KE

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007033Biotechnology and Biological Sciences Research Council BBS/E/I/00007036
6 · The paper itself

Abstract

backgroundRift Valley fever virus (RVFV) is a zoonotic arbovirus that causes severe disease in livestock and humans. The virus has caused recurrent outbreaks in Africa and the Arabian Peninsula since its discovery in 1931. This review sought to evaluate RVFV seroprevalence across the African continent in livestock, wildlife and humans in order to understand the spatio-temporal distribution of RVFV seroprevalence and to identify knowledge gaps and areas requiring further research. Risk factors associated with seropositivity were identified and study designs evaluated to understand the validity of their results. METHODOLOGY: The Preferred Reporting of Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to produce a protocol to systematically search for RVFV seroprevalence studies in PubMed and Web of Science databases. The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement guided the evaluation of study design and analyses. PRINCIPAL

findingsA total of 174 RVFV seroprevalence studies in 126 articles fulfilled the inclusion criteria. RVFV seroprevalence was recorded in 31 African countries from 1968 to 2016 and varied by time, species and country. RVFV seroprevalence articles including either livestock and humans or livestock and wildlife seroprevalence records were limited in number (8/126). No articles considered wildlife, livestock and human seroprevalence concurrently, nor wildlife and humans alone. Many studies did not account for study design bias or the sensitivity and specificity of diagnostic tests.

conclusionsFuture research should focus on conducting seroprevalence studies at the wildlife, livestock and human interface to better understand the nature of cross-species transmission of RVFV. Reporting should be more transparent and biases accounted for in future seroprevalence research to understand the true burden of disease on the African continent.

Indexed as

Animals, WildLivestockRift Valley FeverRift Valley fever virusAfricaAnimalsAntibodies, ViralHumansObservational Studies as TopicSeroepidemiologic StudiesAntibodies, Viral

Identifiers

PMID30036382
PMCPMC6072204
OpenAlexW2884538601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.